Research Company ScienceMachine Secures $3.5 Million Funding for Pioneering AI Applications in Biotechnology Research
ScienceMachine, a London-based AI startup founded in 2025, is making waves in the biotech and pharmaceutical sectors by accelerating data analysis and discovery. With a focus on automating complex data tasks, the company aims to revolutionise the way these industries conduct research.
The company's flagship innovation is an autonomous AI agent named Sam. This AI agent functions as a 24/7 AI bioinformatician, automating the entire data analysis pipeline for biotech and pharma companies. Sam integrates directly with existing databases and lab workflows, processing experimental data to find patterns, insights, and potential breakthroughs without manual intervention.
ScienceMachine has successfully raised €2.9 million in pre-seed funding, led by Revent and Nucleus Capital, with participation from strategic angels. The funding round will support product development and hiring, particularly in sales and pharma partnerships.
Maximilian Schwarz, General Partner at Nucleus, is confident that agent-based architectures will become the leading interface for scientific software. He believes that ScienceMachine is ideally positioned to speed up iteration cycles, increase the addressable market, and accelerate R&D timelines.
The funding round highlights strong investor confidence in ScienceMachine's technology and vision. Rebecca Brill, Principal at Revent, finds ScienceMachine one of the most impressive examples of pure execution, delivering measurable value to customers.
Early customers report achieving results a third of the time, at a fraction of the price, and of a higher quality compared to their own efforts. Sam provides researchers with the same output that would normally require an entire team of data scientists, significantly accelerating their work.
ScienceMachine solves a problem in biomedical research: the lack of data scientists and the struggle of domain experts to run sophisticated biotech analyses, leading to delayed or missed scientific breakthroughs. The startup's AI agent, Sam, is designed to cut costs and speed up scientific discovery by automating data analysis.
Since its launch, ScienceMachine has secured multiple contracts and has a fast-growing pipeline driven by inbound interest. The company's goal is to help biopharma make groundbreaking discoveries faster and cheaper.
[1] https://www.sciencemachine.ai/ [4] https://www.sciencemachine.ai/blog/sciencemachine-raises-3-5-million-to-automate-biotech-data-analysis [5] https://techcrunch.com/2025/09/01/sciencemachine-raises-3-5-million-to-automate-biotech-data-analysis/
After successfully securing €2.9 million in pre-seed funding, ScienceMachine is planning to invest in product development and hiring, with a focus on the sales and pharma partnership sectors. This AI startup's innovative AI agent, Sam, is designed to automate complex data tasks in the biotech and pharmaceutical sectors, revolutionizing the way these industries conduct research. Sam integrates directly with existing databases and lab workflows, providing researchers with high-quality results at a fraction of the time and cost, compared to traditional methods. The company's goal remains to help biopharma make groundbreaking discoveries faster and cheaper, ultimately speeding up R&D timelines and contributing significantly to scientific advancement.
